DRUG PRIOR AUTHORIZATION COMMITTEE September 14, 2006

TENTATIVE AGENDA

<u>IENTATIVE AGENDA</u>			
10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman	
10:05 - 10:15	Minutes Review	Discussion/ Approval	
10:15- 11:15	Pharmacy Program/ Budget Update	George Oestreich/ Andrew Haslag	
11:15 - 11:20	DUR Update	Tisha Honse	
11:20 – 11:30	Old Business Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	George Oestreich	
11:30 – 11:45	New Drug/Product Reviews a. Proposed Actions (See website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. PDL Products iv. Prior Authorization	George Oestreich/ Rhonda Driver	
11:45:1:00	Proposed New Program Actions of Existing Products a. Clinical Edits i. Emend Edit Change • Discussion • Public Hearing • Decision b. Fiscal Advisory i. ADHD Agents • Discussion • Public Hearing	George Oestreich/ Rhonda Driver	

- Decision

ii. **SSRI Antidepressants**

- Discussion
- Public Hearing
- Decision

iii. SNRI Antidepressants

- Discussion
- Public Hearing
- Decision

Iv. Atypical Anti-psychotics

- Discussion
- Public Hearing
- Decision

v. Anticonvulsants

- Discussion
- Public Hearing
- Decision

Drug List (PDL)

Ace Inhibitors

- Discussion
- Public Hearing
- Decision

ii. Ace Inhibitor/Diuretic Combination

- Discussion
- Public Hearing
- Decision

iii. Ace Inhibitor/Calcium Channel Blocker Combination

- Discussion
- **Public Hearing**
- Decision

iv. Angiotensin Receptor Blockers

- Discussion
- Public Hearing
- Decision

v. Angiotensin Receptor Blocker/Diuretic Combination

- Discussion
- Public Hearing
- Decision

vi. Long-Acting Narcotics

- Discussion
- Public Hearing
- Decision

vii. Bone Ossification suppression Agents/Calcitonins

- Discussion
- Public Hearing
- Decision

viii. Nasal Steroids

- Discussion
- Public Hearing
- Decision

ix. Non-Sedating Antihistamines

- Discussion
- Public Hearing
- Decision

x. Non-Sedating Antihistamines Combination

- Discussion
- Public Hearing
- Decision

xi. Alpha-Glucosidase Inhibitors

- Discussion
- Public Hearing
- Decision

xii. Biguanides

- Discussion
- Public Hearing
- Decision

xiii. Biguanide Combination

- Discussion
- Public Hearing
- Decision

xiv. Meglitinides

- Discussion
- Public Hearing
- Decision

xv. 2nd Generation Sulfonylureas

- Discussion
- Public Hearing
- Decision

xvi. Thiazolidnediones (+Combination)

- Discussion
- Public Hearing
- Decision

xvii. Leukotriene Modifiers

- Discussion
- Public Hearing
- Decision

xviii. Macrolides (Adult and Pediatric)

- Discussion
- Public Hearing
- Decision

xix. Quinolones (Systemic)

- Discussion
- Public Hearing
- Decision

xx. Serotonin Receptor Agonists (Triptans)

- Discussion
- Public Hearing
- Decision

Multiple Sclerosis Agents xxi.

- Discussion
- **Public Hearing**
- Decision

xxii. **Topical Immunomodulators**

- Discussion
- **Public Hearing**
- Decision

Immunomodulators xxiii.

- Discussion
- **Public Hearing**
- Decision

xxiv. **Ophthalmic Antihistamines**

- Discussion
- **Public Hearing**
- Decision

Ophthalmic Mast Cell Stabilizers XXV.

- Discussion
- **Public Hearing**
- Decision

Ophthalmic Quinolones xxvi.

- Discussion
- **Public Hearing**
- Decision

xxvii. **Otic Quinolones**

- Discussion
- **Public Hearing**
- Decision

d. **Preferred Drug List**

- **Process Discussion**
- Therapeutic classes/ To be announced at meeting.

LUNCH 1:00

1:15-1:30 **Program Utilization Information** Rhonda Driver

1:30-1:50 Other Business

- "Top 25" Drugs by Cost Clinical Edit Summary Report
- Call Center Statistics

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

Executive Session

1:50-1:55	Minutes Review	Discussion/Approval
1:55-2:30	Case Reviews	Rhonda Driver

NEXT MEETING: December 14, 2006 - 205 Jefferson Street, 10th Floor